First patient in UK epilepsy study got off to a good start

18-07-2019
Today, the first patient in our UK-study commences continuous recording of her brain waves via the long-term monitoring device, UNEEG 24/7.
The patient will live with the implant for one year in order to investigate the feasibility of predicting seizures in people with epilepsy. Ten people with epilepsy will be included in this research innovation project that is part of a $3 million programme funded by The Epilepsy Foundation of America in 2018 and continues over three years. The research project in the UK is headed by Professor Mark Richardson at one of the world’s leading centres for treatment of epilepsy, King’s College London and King’s College Hospital.

By using the advanced UNEEG 24/7 technology the project obtains continuous brain wave recordings from the only device in the market for long-term monitoring of EEG. The invention is the first of its kind in the world and consists of two elements: a discreet implant, inserted under the skin behind the patient’s ear, and a wireless mobile EEG recorder which constantly monitors the brain’s electrical activity, epileptic seizures and potential predictive patterns. The technology is supported by UNEEG EpiSight -  an advanced EEG data analysis software solution.

Prof. Richardson says: “With the new subcutaneous EEG technology, we have the potential to help a considerable number of people with epilepsy. We know that it can be very difficult for a person with epilepsy to keep an accurate record of their seizures. The technology will provide us with an objective measure of their seizure frequency and hence enable us to optimize their treatment”.

If it is possible to predict seizures, it could mean a huge improvement in quality of life for some people. Many people with epilepsy describe the unpredictability of seizures as the most stressful and disabling aspect of having epilepsy. Providing a warning signal would not only tell a person with epilepsy when the risk of having a seizure is high, but also when they would be at low risk”, Prof. Richardson concludes.

In 2017, the UNEEG 24/7 technology won the prestigious Epilepsy Foundation of America’s Shark Tank Prize, which is awarded for the most innovative new ideas in treatment and care of people with epilepsy. Our technology recently gained CE approval is commercially available in the market for long-term EEG monitoring.
 

The only device on the market for long-term monitoring of EEG recently gained CE-approval

Lack of knowledge about the patient’s brain activity has often made it difficult to optimize and adjust medicine use in the treatment of epilepsy, but it has now become possible with the new system that is available commercially in the market.

According to the World Health Organization, epilepsy is the most common serious brain disorder worldwide with no age, racial, social class, national or geographic boundaries. More than 65 million people around the world live with epilepsy, and 30 to 40 percent of people with epilepsy are not able to control their seizures with available treatments. The initial target group for UNEEG 24/7 is the 30% of people who are most affected by epilepsy and who are not responding sufficiently to conventional medical treatment. 

The invention is the first of its kind in the world and consists of two elements: a discreet implant, inserted under the skin behind the patient’s ear, and a wireless mobile EEG recorder which constantly monitors the brain’s electrical activity, thus recording epileptic seizures. Everything is supported by an app and advanced software. The implant is powered by induction and can therefore remain under the skin, as no battery is necessary. The implant is inserted during a 15-minute outpatient operation and causes no serious side effects to the patient.

The implant has so far been approved for adults, but we aim to have it approved for children, too.